Skip to main content

Table 1 Characteristics of studies included in meta-analysis

From: Severity and mortality of COVID 19 in patients with diabetes, hypertension and cardiovascular disease: a meta-analysis

Reference numbers First author Type of study Location Sample size Morbidities (HAS/DM/DCV/ACE OU BRA) Outcome (severity and/or mortality)
[14] Li et al. Case Series CHINA 362 HAS/DM/DCV/ACEI/ARB uses Severity and Mortality
[15] Giamarellos-Bourboulis et al. Case Series GREECE 54 DM/DCV Severity
[16] Zhang et al. Retrospective Cohort CHINA 19 HAS/DM/DCV Mortality
[17] Zhou et al. Retrospective Cohort CHINA 191 HAS/DM/DCV Mortality
[18] Colombi et al. Retrospective Cohort ITALY 236 DM/DCV Severity
[19] Li et al. Cross Sectional CHINA 548 HAS/DM/DCV/ACEI/ARB use Severity
[20] Lei et al. Retrospective Cohort CHINA 34 DM/DCV Severity
[21] Deng et al. Retrospective Cohort CHINA 112 HAS/DM/DCV Severity
[22] Guo et al. Case Series CHINA 187 HAS/DM/DCV/ACEI/ARB use Severity
[23] Huang et al. Retrospective Cohort CHINA 41 HAS/DM/DCV Severity
[24] Zhang et al. Case Series CHINA 140 HAS/DM/DCV Severity
[25] Liu et al. Retrospective Cohort CHINA 78 HAS/DM/DCV Severity
[26] Wang et al. Retrospective Cohort CHINA 138 HAS/DM/DCV Severity
[27] Guan et al. Retrospective Cohort CHINA 1099 HAS/DM/DCV Severity and Mortality
[28] Wu et al. Retrospective Cohort CHINA 84 HAS/DM/DCV Mortality
[29] Zhang et al. Retrospective Cohort CHINA 221 HAS/DM/DCV Severity
[30] Chen et al. Retrospective Cohort CHINA 274 HAS/DM/DCV Mortality
[31] Deng et al. Retrospective Cohort CHINA 225 HAS/DM/DCV Mortality
[32] Wang et al. Case Series CHINA 69 HAS/DM/DCV Severity
[33] Yang et al. Retrospective Cohort CHINA 52 DM/DCV Mortality
[34] Guan et al. Case Series CHINA 1590 DM/DCV Mortality
[35] Zheng et al. Retrospective Cohort CHINA 161 HAS/DM/DCV Severity
[36] Fan et al. Retrospective Cohort CHINA 21 HAS/DM/DCV Mortality
[37] Yuan et al. Case Series CHINA 27 HAS/DM/DCV Severity
[38] Feng et al. Retrospective Cohort CHINA 476 HAS/DM/DCV Severity
[39] Mao et al. Case Series CHINA 214 HAS/DM/DCV Severity
[40] Wang et al. Retrospective Cohort CHINA 339 HAS/DM/DCV Mortality
[41] Simonet et al. Retrospective Cohort FRANCE 124 HAS/DM/DCV Severity
[42] Chen et al. Cross Sectional CHINA 150 HAS Severity
[43] Wu et al. Retrospective Cohort CHINA 201 HAS Severity
[44] Xiang et al. Cross Sectional CHINA 49 HAS Severity
[45] Wan et al. Cross Sectional CHINA 135 HAS/DM/DCV Severity
[46] Qin et al. Retrospective Cohort CHINA 452 HAS Severity
[47] Ruan et al. Retrospective Cohort CHINA 150 HAS Mortality
[48] Zhang et al. Retrospective Cohort CHINA 1128 ACEI/ARB use Mortality
[49] Xu et al. Retrospective Cohort CHINA 187 HAS Mortality
[50] Meng et al. Case series CHINA 42 ACEI/ARB use Severity
[51] Yang et al. Retrospective Cohort CHINA 125 ACEI/ARB use Severity
[52] Mancia et al. Retrospective Cohort ITALY 6272 ACEI/ARB use Severity
[53] Reynolds et al. Retrospective Cohort USA 2005 ACEI/ARB use Severity
  1. DM, diabetes mellitus; HAS, hypertension; DCV, cardiovascular disease; ACEI/ARB, angiotensin converting enzyme inhibitors/angiotensin II receptor blockers